Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?

Published by: Decision Resources

Published: Sep. 18, 2009 - 24 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Technology Strategies—Will They Pay Off?

The Industrialization of Drug Discovery

Biologics Platforms

Enlight Biosciences: Big Pharma’s Technology Collaboration

Organizational Structures and Strategies

GlaxoSmithKline

Novartis

Pfi zer

Sanofi -Aventis

Building R&D Through Business Development

Pharma-Pharma Partnering

AstraZeneca and Merck: Early-Stage Development for Cancer

GlaxoSmithKline and Pfi zer: A Joint Venture for HIV

Moving R&D to China and India

Outlook for Pharmaceutical R&D

Tables

1. Top-Selling Biologic Drugs

2. Bristol-Myers Squibb’s “String of Pearls” Deals

3. GlaxoSmithKline/Pfi zer HIV Joint Venture Portfolio

Figures

1. Combined R&D Expense vs. New Molecular Entity Approvals for 15 Top Pharmaceutical Companies, 2000-2008

2. Business Model for Enlight Biosciences

3. Simplifi ed Scheme of the Mechanisms of Action of MK-2206 and AZD-6244

Abstract

Introduction

Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as creating more entrepreneurial environments modeled upon biotech companies—increase their productivity? Many major companies are reorganizing the research branches of their businesses and fi nding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures.

Questions Answered in This Report
  • In recent years, drug developers have invested heavily in various R&D technologies. Is this investment
    • increasing R&D productivity? What technology strategies are most promising? What new approaches are pharmaceutical companies using to access enabling technologies for drug discovery?
  • Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
    • What steps are leading companies taking to change R&D? What structures and strategies have already been implemented within Big Pharma R&D organizations? Can pharmaceutical companies replicate the innovation of biotech companies by reforming R&D?
  • Biotech companies are an important source of novel technologies and drug candidates. How do acquisitions
    • of and collaborations with biotech companies fi t into Big Pharma’s R&D strategies? How can companies use business development activities to build up technological capabilities and pipelines?
  • Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.
    • Which companies have recently formed innovative partnerships that include early-stage development? What are the key features of these arrangements? How do these ventures meet the strategic needs of both partners?
Scope
  • Technology strategies: Use of high-throughput technologies and R&D productivity, biologics
    • platforms, pharma-pharma ventures for enabling technology development.
  • Organizational structures and strategies: Restructuring R&D, emulating biotech, case
    • studies of R&D reorganization.
  • Building R&D through business development: M&As, collaborations, R&D strategies.
  • Pharma-pharma partnering: Strategic alliances among Big Pharma companies, Phase I
    • codevelopment collaboration, therapeutic area joint venture.
  • Outsourcing R&D: China, India, potential advantages and disadvantages.
  • Outlook for pharmaceutical R&D: Changing business models, personalized medicine,
    • pursuing novel targets, collaboration, high-throughput strategies, translational medicine.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2010